Cutaneous squamous cell carcinoma from the head and neck typically metastasize to the lymph nodes of the neck and parotid glands. When a primary is not identified, they are difficult to distinguish from metastases of mucosal origin and primary salivary gland squamous cell carcinoma. UV radiation causes a mutation pattern that predominantly features cytosine to thymine transitions at dipyrimidine sites and has been associated with cutaneous squamous cell carcinoma. In this study, we used whole genome sequencing data from 15 cutaneous squamous cell carcinoma metastases and show that a UV mutation signature is pervasive across the cohort and distinct from mucosal squamous cell carcinoma. The mutational burden was exceptionally high and concentrated in some regions of the genome, especially insulator elements (mean 162 mutations/megabase). We therefore evaluated the likely impact of UV-induced mutations on the dipyrimidine-rich binding site of the main human insulator protein, CCCTC-binding factor, and the possible implications on CCCTC-binding factor function and the spatial organization of the genome. Our findings suggest that mutation signature analysis may be useful in determining the origin of metastases in the neck and the parotid gland. Furthermore, UV-induced DNA damage to insulator binding sites may play a role in the carcinogenesis and progression of cutaneous squamous cell carcinoma.
INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer (Gurudutt and Genden, 2011) and most primaries arise in the skin of the face and scalp.
Regional lymph node metastases to the neck and the intraparotid nodes occur in up to 5% of patients, entailing significant morbidity and mortality (DʼSouza and Clark, 2011) . When metastatic squamous cell carcinoma of unknown primary is diagnosed in neck lymph nodes or the parotid gland, it is sometimes impossible to determine the primary site based on clinicopathologic features alone. The potential tissues of origins include skin, mucosa, or the salivary gland. The few studies using massive parallel sequencing on cSCC demonstrate that the variability of affected genes is high and there is extensive overlap with SCC from mucosal surfaces, making gene mutation assessment alone an unreliable differentiator Lawrence et al., 2015; Pickering et al., 2014; South et al., 2014) .
DNA mutation patterns may offer a solution to differentiating skin-derived SCC metastases from those originating from other primary sites. Nik-Zainal et al. (2012) demonstrated that mutation patterns can be distinguished when considering the region immediately surrounding each somatic mutation, that is, the trinucleotide context. The relative contribution of recognized mutation signatures can be quantified, providing insights into the exposure of the tumor to various mutagenic agents. Since this initial report, a growing number of signatures with known associations have been reported . Ultraviolet radiation (UV) is the main risk factor for the development of cSCC and predominantly causes DNA mutations at dipyrimidine sites, where it induces CT transitions (Douki and Cadet, 2001; Marteijn et al., 2014) . Studies using targeted or whole-exome sequencing have observed predominance of CT transitions in mostly primary cSCC (Durinck et al., 2011; Pickering et al., 2014; South et al., 2014; Zilberg et al., 2018) . Other mutational processes also cause CT mutations (Forbes et al., 2017) , but trinucleotide mutation signature analysis is able to resolve the underlying mutagenic agents, and identify UV-specific CT mutations.
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The distribution of these mutations is uneven across the genome and affects specific regions more than others (Perera et al., 2016) . Because of its high dipyrimidine content, the binding site of the main human insulator, CCCTC-binding factor (CTCF), is especially susceptible to UV-induced mutations. CTCF may play an important role in carcinogenesis, as it regulates the transcriptional activity of topologically associated domains (TADs), which represent chromatin loops harboring multiple genes (Hnisz et al., 2016; Kemp et al., 2014) .
Here, we analyze genome-wide mutations in regard to their trinucleotide context, present the first signature analysis of cSCC metastases and explore its clinical utility. We further assess the distribution of UV-induced mutations across the genome, and assess the potential impact on CTCF using the approach described by Poulos et al. (2016) in melanoma.
RESULTS

Patient Characteristics
Six parotid and nine neck lymph node cSCC metastases from 15 patients were included (Table 1 ). The site of the cSCC primary was unknown in four patients. Two patients received immunosuppressive therapy.
Mutational Patterns Across the Genome
Average coverage of whole genome sequencing (WGS) was 83.0× in tumors and 37.9× in blood. The total number of somatic mutations per sample ranged from 136,105 to 1,423,398 (mean 638,254; Figure 1a ). Mutations occurred mostly in non-coding regions (99.4%), and mutation density was 171 times higher for non-coding variants compared to coding variants (mean 206.6 vs. 1.2 mutations/Mb, median 168.3 vs. 0.9 mutations/Mb respectively; Figure   1a and 1b). Assessment of the distribution of somatic mutations across broad genome region categories indicated excessive mutation density in insulators (162 mutations/Mb; Figure 1c ).
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The mutations recovered were predominantly CT transitions (average 82.5%, range 76.1% to 90.8%; Figure 1d ).
Mutation Signature Analysis
De novo analysis revealed three predominant mutation signatures in our cohort (Signature I, II, III; Figure 2a ), which clustered with previously reported signatures 7a and 7b Figure 2b ). Signature 7 features predominantly CT mutations, and the subsignatures 7a, 7b, 7c, and 7d are driven by different mutational processes triggered by UV exposure . Signatures 7a and 7b may reflect direct impact of photoproducts, while 7c and 7d may represent indirect processes such as erroneous repair . Signatures 7a and 7b were observed in all samples, while 7c and 7d were present in four and two cases, respectively ( Figure 2c ). Signature 32 was strongly evident in a single patient (case 06). Signature 58, thought to denote a sequencing artifact, was present in seven of the 15 cases (46.7%), and its presence was not associated with tumor burden, or the sequencing laboratories.
Analysis of published whole-exome data of six metastases and 26 primary cSCC (Pickering et al., 2014) , demonstrated similar dominance of signatures 7a and 7b in both primaries and metastases, while the heterogeneity of other contributing signatures was greater than in our cohort ( Figure 2d ). To assess whether the signature pattern allows the distinction of cSCC from mucosal SCC, signature analysis on whole-exome data of 44 oral cavity SCC primaries from The Cancer Genome Atlas (TCGA; Lawrence et al., 2015) was performed (Figure 2e ).
Most (41 of 44) oral cavity SCC featured a clearly distinct mutation pattern. Two samples from the lip (a UV exposed site) and another for which the anatomical location was not specified showed similar signatures to our cSCC cohort.
CTCF binding Site Mutations
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The high prevalence of mutations in insulator regions prompted an investigation of the mutational distribution at DNA binding sites of CTCF, the main human insulator protein. We applied a strict 13 base pair (bp) motif as previously described (Figure   3a ), excluding three low-confidence bp at both ends of the consensus CTCF binding site (CTCFbs) motif of the JASPAR database (Mathelier et al., 2016) . The number of recognized CTCFbs totaled 5,470. The mutation density at CTCFbs was significantly increased compared to their flanking regions ( Figure 3b ) and mutations were predominantly CT transitions ( Figure 3c ). The average number of mutated motifs per sample was 84.5 per Mb (range 14 to 223; median 64; IQR 30.5 to 116.5). Across the cohort, a total of 1,404 mutations were detected at the 5,470 examined sites, which showed little overlap between patients: 1,026 (18.8%) motifs were mutated in only one sample, while 219 (4.0%) were mutated in two, 42 (0.8%) in three, and 22 (0.4%) were mutated over four samples. When regarding both, the upper and the lower strand of the DNA, the conserved 13 bp CTCF motif harbors cytosine in up to 11 positions (minimum 7) and accounts for up to eight pyrimidine pairs, three of which are highly conserved (Douki and Cadet, 2001; Marteijn et al., 2014) (Figure 2a ). Throughout the cohort, the highest mutation density was detected at dipyrimidine positions 10 and 11 (Figures 3d, 3e) . When we repeated the analysis using control motifs that only match positions 8 to 13 of the motif , the predilection for mutations in positions 10 and 11 was nearly eliminated (Figure 3d ), proving that it only occurs in the context of a conserved CTCFbs.
The potential impact of the CTCFbs mutations on TADs was then assessed. From an initial 4929 TADs identified in normal human epidermal keratinocytes (NHEK) (Rao et al., 2014) , 903 TADs with CTCFbs at both ends were extracted ( Figure 4a ). Of these, 422 (46.7%) were identified to have a mutated CTCF motif in at least one of the delimiting anchor regions (across the cohort), and 47 (5.2%) had mutations in both anchor regions. Within the affected loops, we detected 1,979 genes, including 38 oncogenes (Liu et al., 2017) , 52 tumor suppressor genes (Zhao et al., 2016) , and eleven identified as potential tumor drivers (Bailey et al., 2018;  Table 2 ). Analysis of a subset (30) of these genes located in the affected TADs did not correlate with a change of expression levels between samples that carried the CTCFbs mutations and those that did not ( Figure S2 ).
DISCUSSION
Metastases of cSCC Exhibit UV-Induced Mutation Signatures
This is the first study to apply WGS and signature analysis on metastases of head and neck cSCC. Our results confirm that UV-associated mutation signature 7 is present in both cSCC primaries and metastases (Figure 2c, 2d) , and that the mutation signature pattern clearly differs from that of mucosal human papilloma virus (HPV) negative head and neck SCC primary lesions (Figure 2e ). The mutation analysis of oral cavity SCC was performed on primaries, as we are not aware of publicly available data for metastases of mucosal SCC.
However, we assume that their signatures correspond to those found in metastases, as we have shown for cSCC in this study (Figure 2c, 2d) . Notably, the TCGA oral cavity SCC cohort includes lip tumors (Figure 2e ), which are no longer classified as oral cavity SCC by the AJCC, but as cSCC as most are solar induced (Amin et al., 2017) .
Thus, algorithmic signature analysis is able to distinguish cSCC metastasis from squamous cell carcinoma of different origin. This distinction is impossible based on clinical or histopathological parameters alone, except in the case of HPV positive oropharyngeal SCC (Satgunaseelan et al., 2017) , and is clinically relevant with regards to prognosis and treatment.
Four patients in our cohort had no known primary lesion. All four patients were Anglo-celtic Australians who had acquired actinic damage to the skin of the head, and mucosal examination was unremarkable, making a cutaneous origin of their parotid metastases highly probable. Consistently, UV-signature was strongly present in the tumor tissue of all four patients ( Figure 2c ). Apart from mucosal SCC, signature analysis may also help to distinguish cSCC from primary SCC of the salivary gland, an extremely rare entity that is to date a diagnosis of exclusion. Many of these presumed primaries may in fact represent metastases for which a cutaneous primary was not recognized (Chen et al., 2015) , especially in the parotid gland. Due to the rarity of this entity and the subsequent lack of published sequencing data, its signature profile is unknown, but a significant UV-associated signature is unlikely.
The predominance of CT transitions is not unique to UV-induced damage, being associated with other factors (e.g. ageing processes, alkylating agents exposure), and delivers insufficient information to clearly distinguish mutation patterns. Signature analysis based on the trinucleotide context overcomes this problem. The extent of the contribution of signatures other than UV-signature is variable, and depends on the type of analyzed data. We believe that the increased heterogeneity in signatures derived from the whole-exome data of Pickering at al. ( 2014) compared to our WGS data (Figure 2c, 2d ) is because the great majority of mutations in cSCC are located in the non-coding DNA (Figure 1a ). Thus, WGS increases the power of signature analysis. The publicly available data from Pickering et al. (2014) is filtered, which may also have an impact on signatures. Furthermore, the reduced effectiveness of repair mechanisms in the non-coding DNA (Budden and Bowden, 2013; Frigola et al., 2017 ) may also be reflected in signature analysis of WGS data. Consistent with recent work by Inman et al. ( 2018) , case 06, who was under azathioprine treatment for rheumatoid arthritis, showed strong contribution of signature 32 (Figure 2c ).
Azathioprine increases the risk of skin cancer through inhibition of nucleotide excision repair (NER) of UV-induced DNA damage (Coghill et al., 2016) . Azathioprine causes a CA bias (Zhang et al., 2007) , which occurs alongside the UV-induced CT mutations, and is the hallmark of Signature 32. Consistently, the rate of CA transitions was more than double in case 06 compared to all others (6.89% vs. mean 2.97%, range 1.43 to 4.1%, Figure 1d ).
UV-induced Mutations at Insulator Sites
The mutational burden was 171-fold higher in the non-coding regions than in coding regions of the genome (Figures 1a, 1b ). This concentration may reflect less effective mismatch repair in non-coding regions (Frigola et al., 2017) and the higher priority of the transcription coupled NER compared to global NER (Budden and Bowden, 2013) . The subsequently identified concentration of mutations in insulator regions ( Figure 1c ) may have implications on regulatory processes. Considering that a specific tumor driving gene pattern has not yet emerged in cSCC, such alternative carcinogenic models are of special interest. We therefore assessed the main human insulator CTCF, whose DNA binding site seems prone to UVinduced damage because of its high cytosine and dipyrimidine content. CTCF simultaneously binds to specific base pair sequences at multiple DNA sites, thereby approximating distant chromatin regions and forming 3-dimensional DNA loops termed topologically associated domains (TADs; Hnisz et al., 2016; Kemp et al., 2014) . These can incorporate multiple genes, whose expression is dependent on the binding status of CTCF (Holwerda and de Laat, 2013;  Ong and Corces, 2014; Figure 4b ). Loss of CTCF function through mutation of its binding site can disrupt TADs and alter the transcriptional activity of the associated genes. This can affect the cell phenotype and potentially plays a role in carcinogenesis (Hanssen et al., 2017; Hnisz et al., 2016; Kemp et al., 2014; Tang et al., 2015) .
We observed mutated CTCFbs in all 15 cases and the prevalence was considerably higher compared to melanoma ) (mean 84.5 vs. 11.4 mutated motifs/patient).The mutation density in the CTCF motif was not only higher than in the flanking region, but exceeded the expected concentration based on the high cytosine and dipyrimidine content (Figure 3b, 3cc ). This clustering of mutations at the CTCFbs was not only previously described in melanoma , but also in colorectal cancer, which is not UV associated (Katainen et al., 2015) , and is explained by the fact that bound CTCF blocks access of NER enzymes to the CTCFbs (Sabarinathan et al., 2016) . Consistently, cSCC patients with dysfunctional NER have comparable mutation density at flanking regions and CTCF motifs . Interestingly, the two cases in our cohort under treatment with immunosuppressants known to inhibit NER, did not exhibit flattening of the mutational peak at the CTCFbs ( Figure S1 ). However, this could be explained by the fact that NER is only partially deactivated by these immunosuppressants, whereas the impact of XPC-deficiency is more deleterious (Budden and Bowden, 2013; Kuschal et al., 2012) . Finally, mutations were unevenly distributed within the CTCF motif. Strikingly, dypirimidine positions 10 and 11 comprised the vast majority of all mutations, whereas mutation density was comparably low at other dipyrimidine or cytosine positions (Figure 3c, 3d ). This is consistent with findings by Poulos et al. (2016) , who suggest that differential rates of repair at specific motif positions cause this asymmetry.
Assuming that CTCF cannot efficiently bind modified binding sites, mutations potentially result in disruption of TADs and dysregulation of their enclosed genes (Figure 4b ). Even our conservative approach yielded 1,979 genes within 422 affected TADs and included tumor suppressor genes and oncogenes. (Table 2) . We cannot ascertain at this stage whether the identified mutations at CTCFbs contribute to carcinogenesis or are just passenger mutations.
Using Nanostring technology we did not detect significant changes in expression for genes that were located within affected TADs when compared to samples in which the same TAD was not affected (total genes tested = 30; Figure S2 ). However, an adequate determination of differential expression would require much larger cohorts (including UV-affected normal skin) and gene panels. Poulos et al. ( 2016) reported similar issues even when using RNA-Seq in 36 melanoma samples. Nevertheless, they were able to show that expression of cancerassociated genes in affected TAD loops was statistically different from wildtype TAD loops.
Ultimately, the assessment of the clinical impact of CTCFbs mutations on gene expression and carcinogenesis in cSCC would require functional analysis using patient-derived primary cell cultures.
Conclusion
Mutation signature analysis has potential future clinical use, as it allows cSCC metastases to be distinguished from other SCC when a primary cannot be identified. This is of particular value given the absence of uniquely characteristic driver gene mutations in cSCC. An alternative mechanism to driver gene mutations in cSCC may lie in UV-induced damage to regulatory elements in the DNA, such as the heavily mutated binding site of the insulator and master transcription factor CTCF assessed in this study. Functional studies are necessary to further explore such possibly carcinogenic models, and future research should therefore also be directed to non-coding and regulatory regions of the DNA.
MATERIALS AND METHODS
Sample Processing and Sequencing
Patients were prospectively enrolled between March 2015 and July 2017. Informed consent and approval from the institutional ethics committee were sought prior to the study (UOW/ISLHD HREC 14/397). Samples were snap frozen and underwent histopathology review to select areas with high neoplastic content (30-90%).
DNA was extracted using Qiagen AllPrep DNA/RNA mini Kit (Qiagen, Venlo, Netherlands).
Quantitation and purity of DNA were measured using NanoDrop spectrophotometry (Thermo Fisher Scientific, North Ryde, Australia). DNA integrity was assessed by agarose gel electrophoresis and in-house analyses. WGS was performed by Genome.One (Darlinghurst, Australia) and Macrogen (Seoul, South Korea) on Illumina HiSeq X to a depth of 30-45X for normal and 65-90X for tumor samples. Mapping and variant calling was performed as per Tsoli et al. ( 2018) .
Distribution of Mutations and Signature Analysis
The distribution of mutations was assessed across broad genome regions using the heterochromatin regions, the universal promoter and enhancer DHS datasets from Perera et al. (2016) , and the CTCF chromatin immunoprecipitation sequencing (ChIPSeq) data for insulator regions of NHEK from ENCODE (The ENCODE Project Consortium, 2012).
From a 96 trinucleotide mutation count matrix, we extracted signatures de novo applying nonnegative matrix factorization (Brunet et al., 2004) using Maftools (Mayakonda and Koeffler, 2016) in R version 3.5.0 (R Development Core Team, 2008) . We also applied the matrix of mutational signature weights from Alexandrov et al. ( 2018) to assess similarity and coherence of the mutation profiles with recognized signatures usingDeconstructSigs (Rosenthal et al., 2016) . Signatures were reported when attributable mutations contributed >6% in any sample. The same approach was applied on publicly available VCFs from wholeexome sequencing data of cSCC (Pickering et al., 2014) and oral cavity SCC from TCGA (Lawrence et al., 2015) .
CTCF Binding Site Mutation Assessment
To assess mutations at CTCFbs, filtering occurred in two steps to limit false positives, as reported by Poulos et al. (2016) . First, we selected CTCFbs harboring a strict motif including the central 13 bp of the 19 bp consensus motif (Mathelier et al., 2016) . Second, we identified the sites occurring at ChIP-Seq peaks for CTCF in NHEK available from ENCODE, thus assuring that assessed sites have bound CTCF. Binding sites were overlaid with our cohort's WGS data to quantify mutation density at every base in the motif and the neighboring 1kb.
Results were normalized to mutations per megabase. We repeated the analysis using control motifs generated by Poulos et al. (2016) from NHEK ChIP-Seq peaks that only match positions 8 to 13 of the motif, while positions 1 to 7 could be any bases other than those observed in CTCF motifs.
To identify and locate the CTCFbs at boundaries of TADs, we used chromosome conformation capture (Hi-C) TAD maps of NHEK (Rao et al., 2014) and ChIP-seq data from ENCODE. Hereby, a more permissive 20 bp motif is tolerated, and a 20 bp position weighted matrix (Kim et al., 2007) is applied to select for binding sites with high CTCF-binding probability. TADs were filtered as illustrated in Figure 4a . TADs were excluded if they had more than one CTCF binding motif in either anchor region, and if CTCF motifs were not in convergent orientation, since this arrangement has the highest association with binding of CTCF (Rao et al., 2014) . Genomic coordinates delimitating a TAD were defined as the 3'-end of the upstream and the 5'-end of the downstream motif. Genes lying in TADs were identified from the UCSC genome browser (Kent et al., 2002) using BEDTools (Quinlan and Hall, 2010) .
Gene expression analyses
RNA was extracted using Qiagen AllPrep DNA/RNA mini Kit (Qiagen, Venlo, Netherlands).
Quantitation and purity of RNA were measured using NanoDrop spectrophotometry (Thermo Fisher Scientific, North Ryde, Australia). RNA expression was evaluated by NanoString nCounter Sprint system using the PanCancer Progression panel (Nanostring, Seattle, WA, USA) as per the manufacturer's instructions. Results were analyzed using NanoString nSolver 4.0 and Advanced Analysis Module (Nanostring, Seattle, WA, USA), which normalizes gene expression to a set of positive and negative controls genes. The expression of genes found in a mutated TAD in at least one sample in our cohort was compared to that of the other samples of the cohort using a heatmap. Table 2 . Genes located in TAD loops with mutated CTCF motifs across the cohort of 15 cSCC lymph node metastases which are recognized as tumor suppressor genes (TSGene, Zhao et al., 2016) oncogenes (ONGene, Liu et al., 2017) , or identified as potential tumor driver genes (Bailey et al., 2018) .
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